Concepedia

Miro J. Eigenmann

MJ

Statistics

Publications

8

Citations

255

H-Index

8

Active since

2016

Affiliations

Roche (Switzerland)(Current)

Roche Pharma AG (Germany)

Saarland University

Miro J. Eigenmann is an author at Roche (Switzerland) specializing in oncology, pharmacokinetic modeling, and pharmacology.

ORCID

Publications per year

2016–2024

8

Publications

8

Quantification of IgG monoclonal antibody clearance in tissues

Miro J. Eigenmann, Ludivine Fronton, Hans Peter Grimm et al. · mAbs · 2017 · 81 citations · Full text

, , +17

Interstitial IgG antibody pharmacokinetics assessed by combined <i>in vivo</i>‐ and physiologically‐based pharmacokinetic modelling approaches

Miro J. Eigenmann, Tine V. Karlsen, Ben‐Fillippo Krippendorff et al. · The Journal of Physiology · 2017 · 55 citations · Full text

, , +11

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy

Johannes Sam, Thomas Höfer, Christine Kuettel et al. · Blood · 2024 · 37 citations · Full text

, , +17

Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling

Arthur J. Van De Vyver, Tina Weinzierl, Miro J. Eigenmann et al. · Molecular Cancer Therapeutics · 2020 · 25 citations · Full text

, , +17

PKPD modeling of acquired resistance to anti-cancer drug treatment

Miro J. Eigenmann, Nicolas Frances, Thierry Lavé et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2017 · 22 citations · Full text

, , +16

1–5 of 8